Fortress Biotech Earnings Call Transcripts
Fiscal Year 2026
-
The company leverages a scalable, diversified model to acquire and develop clinical-stage medicines, generating value through royalties, equity, and milestones. Recent monetizations and FDA approvals have strengthened cash flow, while AI-driven asset identification and a robust pipeline position the company for continued growth.
-
Q1 2026 saw 21% revenue growth year-over-year, driven by EMROSI’s strong performance and improved profitability. EMROSI prescriptions and revenue per script increased, with expanded payer access and new product launches planned for 2026.
Fiscal Year 2025
-
Q3 2025 saw 21% revenue growth, led by Emrosi's strong launch and rapid prescription uptake. Gross margin improved sequentially, adjusted EBITDA turned positive, and the company expects sustainable EBITDA positivity in Q4. Emrosi is projected to become a leading rosacea therapy.
-
The meeting confirmed a quorum, introduced directors and advisors, and presented five motions for shareholder vote. All director nominees, auditor ratification, and executive compensation proposals passed, while the officer exculpation amendment was not approved.
Fiscal Year 2024
-
2024 revenue met guidance at $56M, with IMROCI FDA-approved and set for launch in early 2025. IMROCI is expected to drive significant growth, with payer coverage ramping over 12–18 months and strong interest from physicians and payers.